Abstract
Abstract
Background
Accidental overdose of low-dose methotrexate can lead to serious patient harm. Different safety measures are recommended to prevent errors, yet, as errors continue to happen, their implementation is questionable.
Aim
To evaluate the implementation status of safety measures for methotrexate in community and hospital pharmacies.
Method
An electronic questionnaire was sent to head pharmacists of 163 community and 94 hospital pharmacies in Switzerland. The implementation of recommended safety measures (general measures, safety working procedures, IT-based measures) was assessed and descriptive analysis performed. An analysis of sales data underlined the relevance of our results, i.e., the population under risk for overdose.
Results
A response was obtained from 53% (n = 87) of community and 50% (n = 47) of hospital pharmacists. Pharmacies had implemented a median of 6 (IQR 3, community) and 5 (IQR 5, hospital) safety measures overall. Most of these were defined safety procedures, instructing staff on how to handle methotrexate prescriptions. Across all safety measures, compliance with single procedures was perceived as “very likely” by 54% of community pharmacies. IT-based measures (e.g., alerts) were absent in 38% (n = 31) of community and 57% (n = 27) of hospital pharmacies. On average, every community pharmacy dispensed 22 packages annually.
Conclusion
Safety in relation to methotrexate in pharmacies relies mostly on staff instructions, which are considered weak measures. In light of the serious risk imposed on patients, pharmacies should set a focus on stronger IT-based measures that rely less on human performance.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference35 articles.
1. European Medicines Agency. PRAC recommends new measures to avoid dosing errors with methotrexate. 2019 Jul. https://www.ema.europa.eu/en/news/prac-recommends-new-measures-avoid-dosing-errors-methotrexate. Accessed 14 July 2022.
2. Weiler S, Jetter A. Panzytopenie unter Methotrexat. Swiss Med Forum. 2017;17:594–6.
3. Institute for Safe Medication Practices (ISMP). ISMP List of high-alert medications in community/ambulatory care settings. 2021. https://www.ismp.org. Accessed 27 Dec 2022.
4. Institute for Safe Medication Practices (ISMP). ISMP list of high-alert medications in acute care setting. 2018. https://www.ismp.org/recommendations/high-alert-medications-acute-list. Accessed 27 Dec 2022.
5. Stiftung Patientensicherheit Schweiz. Never event-liste Schweiz. Zürich; 2021. https://www.patientensicherheit.ch/never-event-liste/. Accessed 27 Dec 2022.